ABLE-41: Nadofaragene firadenovec-vncg early use and outcomes in a real-world setting in the United States. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results